Migenix Amends Protocol in Hepatitis C Study

Migenix will add a 600-mg celgosivir combination therapy arm to its Phase II study in treatment-naive hepatitis C patients.

The 12-week, randomized, active-controlled study initially enrolled 20 patients in two treatment arms: peginterferon alfa-2b plus ribavirin and the combination plus 400-mg celgosivir.

The approved protocol amendment allows for the addition of the 600-mg arm and the flexibility to increase the number of patients in the study to a maximum of 50, Migenix said.